New antibody drug aims to help severe asthma patients breathe easier
NCT ID NCT06680947
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a new antibody drug (called 610) for adults with severe asthma that is not well controlled by standard inhalers. About 225 participants will receive either the drug or a placebo to see if it improves lung function and reduces asthma attacks over 52 weeks. The drug targets a protein involved in airway inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.